Efficacy of 0.05% cyclosporine A on the lipid layer and meibomian glands after cataract surgery: A randomized, double-masked study.
Aged
Anti-Inflammatory Agents
/ therapeutic use
Calcineurin Inhibitors
/ therapeutic use
Cataract Extraction
/ methods
Cyclosporine
/ therapeutic use
Double-Blind Method
Female
Humans
Lipid Metabolism
/ drug effects
Male
Meibomian Glands
/ drug effects
Middle Aged
Tears
/ drug effects
Treatment Outcome
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
04
2020
accepted:
28
12
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
16
6
2021
Statut:
epublish
Résumé
To quantitatively evaluate the effects of 0.05% cyclosporine A (CsA) on lipid layer thickness (LLT) and meibomian glands after cataract surgery using the LipiView® ocular surface interferometer. This study was a prospective randomized double-masked clinical trial conducted by Pusan National University Yangsan Hospital between April 04, 2019, and November 31, 2019. Sixty-two participants were recruited, and 12 of them were not enrolled because they had undergone previous treatments for ocular surface diseases. The participants were adult patients with cataract, exhibiting normal lid position; they did not present any other ocular disease and did not meet the exclusion criteria of the clinical trial. Fifty subjects were enrolled in the study. The randomized subjects received treatment with 0.05% CsA (group A) or 0.5% carboxymethyl cellulose (CMC) (group B) over the 3 months following the cataract surgery. Subjective and objective assessments were performed at preoperative and postoperative visits. Ocular Surface Disease Index (OSDI), tear breakup time (TBUT), and Schirmer's I test were performed by the same surgeon, and LLT and meiboscore were determined using the LipiView® interferometer. Fifty subjects subjects enrolled consisted of men (50%) and women (50%), with a mean (SD) age of 65.94 (10.35) years. Four subjects in group A and five in group B were excluded from the analysis as they were lost to follow-up within 1 month after cataract surgery. Thus, the study comprised 41 eyes of 41 subjects; 21 subjects were treated with CsA and 20 subjects with CMC. Comparing the clinical measurements between groups A and B taken at the last visit, while controlling the effects of the preoperative values, TBUT and LLT showed significant differences (p = 0.035 and p = 0.047, respectively, by ANCOVA). The TBUT between the subjects using CsA and those using CMC after cataract surgery showed a significant difference during follow up (p = 0.003 by repeated measures ANOVA). In the multivariate analysis, preoperative LLT and the use of CsA were found to be independent parameters for postoperative LLT (R2 = 0.303; p = 0.008 and p = 0.045, respectively), whereas the follow-up duration exhibited a positive correlation with the difference between the preoperative and postoperative values of LLT in the group treated with CsA (R2 = 0.738 and p < 0.001). Treatment with 0.05% CsA following cataract surgery is effective in improving TBUT and LLT in comparison with 0.5% CMC. A higher preoperative value of LLT and the postoperative use of CsA could be significant determinants of a higher postoperative LLT value. ISRCTN registry with ISRCTN 10173448.
Identifiants
pubmed: 33428686
doi: 10.1371/journal.pone.0245329
pii: PONE-D-20-08196
pmc: PMC7799832
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Calcineurin Inhibitors
0
Cyclosporine
83HN0GTJ6D
Banques de données
ISRCTN
['ISRCTN 10173448']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245329Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Indian J Ophthalmol. 2019 Aug;67(8):1297-1302
pubmed: 31332113
Int J Ophthalmol. 2018 Apr 18;11(4):593-600
pubmed: 29675376
Cornea. 2012 Dec;31(12):1386-93
pubmed: 23135530
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4076-83
pubmed: 27537256
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6762-9
pubmed: 26567788
Curr Opin Ophthalmol. 2012 Jan;23(1):68-72
pubmed: 22081034
Surv Ophthalmol. 2009 May-Jun;54(3):321-38
pubmed: 19422961
Korean J Ophthalmol. 2013 Jun;27(3):167-71
pubmed: 23730108
Saudi J Ophthalmol. 2019 Jan-Mar;33(1):34-40
pubmed: 30930661
Korean J Ophthalmol. 2009 Jun;23(2):65-73
pubmed: 19568353
J Cataract Refract Surg. 2002 Aug;28(8):1386-9
pubmed: 12160808
Cont Lens Anterior Eye. 2016 Feb;39(1):15-9
pubmed: 26275686
Biomed Eng Online. 2017 Nov 23;16(1):135
pubmed: 29169367
PLoS One. 2013 Nov 12;8(11):e78657
pubmed: 24265705
Can J Ophthalmol. 2018 Aug;53(4):373-379
pubmed: 30119792
Drugs. 2015 Jul;75(11):1177-85
pubmed: 26130187
Lancet Glob Health. 2013 Dec;1(6):e339-49
pubmed: 25104599
Annu Rev Immunol. 1997;15:707-47
pubmed: 9143705
J Ophthalmol. 2016;2016:9640643
pubmed: 28116143
Clin Ophthalmol. 2013;7:1797-803
pubmed: 24043929
Cornea. 2007 Oct;26(9 Suppl 1):S16-20
pubmed: 17881910
Graefes Arch Clin Exp Ophthalmol. 2009 Jun;247(6):821-9
pubmed: 19101718
Cornea. 2006 Feb;25(2):171-5
pubmed: 16371776
Ophthalmology. 2017 Nov;124(11S):S20-S26
pubmed: 29055358
Eye (Lond). 2002 Sep;16(5):594-600
pubmed: 12194075
Curr Opin Ophthalmol. 2016 Jan;27(1):24-30
pubmed: 26569526
Ophthalmic Physiol Opt. 2008 Mar;28(2):127-34
pubmed: 18339043
Curr Eye Res. 2018 Feb;43(2):155-162
pubmed: 29135324
Ophthalmology. 2009 Nov;116(11):2058-63.e1
pubmed: 19744718